Moderna Inc. is pushing to finalize its submission for FDA authorization of its COVID-19 vaccine for children aged 6 months to under 6 years, with completion expected next week. The company has already requested emergency use authorization, marking it as the first vaccine candidate for this age group, supported by clinical data showing a strong immune response similar to that of adults. Despite a substantial stock decline of over 57% in the past six months, Moderna aims to tackle ongoing vaccine demand and accessibility issues.
“Moderna · sought authorization · its vaccine · for children under the age of 6”
“Moderna · will complete submission · for children aged 6 months to under 6 years · next week”
“Moderna Inc. · has asked · the U.S. Food and Drug Administration · to greenlight its Covid-19 vaccine for children between 6 months and 6 years old”
“Moderna · has FDA filing · COVID vaccine for children · latest information”
“Moderna · filed a request for · emergency use authorization for its COVID-19 vaccine · for use in kids between 6 months and under 6 years”
“Moderna · requested approval for · two doses of the mRNA vaccine · 25 micrograms”
“Moderna · is the first vaccine company to submit its filing · for the still-unprotected age group”
“Moderna · said the submission will be complete by · next week”
“Moderna Inc · asked U.S. regulators to authorize · COVID-19 vaccine for children under the age of 6 · the first shot against the coronavirus available for those under 5-years-old”
“Moderna · released trial data showing that · its vaccine was safe and generated a similar immune response · in young children as for adults”
“Moderna · seeks · FDA approval · COVID-19 shot for children 2-6”
“Moderna · has filed · COVID vaccine for children · authorization”
